FORT WORTH, Texas -- Tim Herron and Tom Pernice, Jr. were named this week's AstraZeneca Charity Challenge winners for their first-place standing entering the final round of the FedEx St. Jude Classic. The AstraZeneca Charity Challenge, formerly known as the CRESTOR® Charity Challenge, is a season-long competition that recognizes and rewards the tournament leader entering the final round at 35 PGA TOUR events. Through the sponsorship, AstraZeneca will donate $3.5 million this year to designated health care charities and will have donated a three-year total of $9.7 million by the conclusion of the 2006 PGA TOUR season.

For Herron and Pernice’s performance, AstraZeneca will donate $100,000 to the American College of Allergy, Asthma and Immunology (ACAAI), on behalf of Herron and Pernice and the FedEx St. Jude Classic.

“The American College of Allergy, Asthma and Immunology, on behalf of its Nationwide Asthma Screening Program, is the proud recipient of the AstraZeneca Charity Challenge,” said William Dolen, M.D., ACAAI president. “With AstraZeneca’s support, we are leading the fight against undiagnosed and uncontrolled asthma and helping people across the country breathe easier. If you're having trouble breathing and don't know why, ask your doctor whether you should be tested for asthma.”

AstraZeneca produces a wide range of products that make significant contributions to treatment options and patient care including CRESTOR, NEXIUM, SEROQUEL, ARIMIDEX, and PULMICORT RESPULES. Through this year’s sponsorship, as part of its commitment to patient health and well being, AstraZeneca will also designate health care related charities across therapeutic areas as recipients at the 35 PGA TOUR events throughout the year.

“AstraZeneca’s partnership with the PGA TOUR is an integral part of our mission of giving back in local communities throughout America,” said Tony Zook, CEO, AstraZeneca U.S. “The AstraZeneca Charity Challenge offers a unique platform for providing important disease awareness, health information and education to make a difference in the lives of patients and consumers everyday.”

The AstraZeneca Charity Challenge is the centerpiece of a multi-year PGA TOUR partnership with AstraZeneca (NYSE:AZN). Last year, AstraZeneca donated $3.5 million through the program. Highlights from the AZCC include:
• Last week the AstraZeneca Charity Challenge co-winners at the Bank of America Colonial were Tim Herron and Rod Pampling. It was Pampling’s second AstraZeneca Charity Challenge victory of 2006 (Bay Hill Invitational was his first) and fourth overall
•  At 16 of the first 18 tournaments of 2006, the AstraZeneca Charity Challenge winner or co-winner went on to win the tournament.
•  More than 85 charities have benefited from the program.
•  Vijay Singh leads all players with eight AstraZeneca Charity Challenge wins. With some of his charitable “winnings,” Singh donated money to the American Red Cross Hurricane Relief Funds in Florida and New Orleans.

• Other multiple winners have included Jim Furyk, Tom Lehman, Phil Mickelson and Rod Pampling (four), Chad Campbell, Luke Donald, Sergio Garcia, Adam Scott and David Toms (three), and the following players who triumphed twice: Stuart Appleby, Bart Bryant, Chris DiMarco, Arron Oberholser, Joe Ogilvie, Kenny Perry, Carl Petterson, Ted Purdy and Tiger Woods.

Fans can log on to www.astrazeneca.pgatour.com to read about past AstraZeneca Charity Challenge winners and learn more about AstraZeneca.

About The American College of Allergy, Asthma and Immunology
The ACAAI is a professional medical organization comprising more than 5,000 qualified allergists-immunologists and related health care professionals. The College is dedicated to the clinical practice of allergy, asthma and immunology through education and research to promote the highest quality of patient care.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. Worldwide, AstraZeneca has six major research and development sites, four discovery facilities and a clinical research site. In total, AstraZeneca’s R&D organization is comprised of more 11,500 people located in seven countries including Canada, France, India, Japan, Sweden, United Kingdom and the United States.